Want to see XFOR full AI Analyst Report?

X4 Pharmaceuticals (XFOR) Price & Analysis

1,120 Followers

XFOR Stock Chart & Stats

$4.17

$0.09(2.34%)

At close: Jul 27 4:00 PM EDT

$4.17

$0.09(2.34%)

Day’s Range― - ―

52-Week Range$2.43 - $4.83

Previous Close$3.86

Volume360.03K

Average Volume (3M)882.73K

Market Cap

$332.14M

Enterprise Value$458.70M

Total Cash (Recent Filing)$207.97M

Total Debt (Recent Filing)$77.22M

Price to Earnings (P/E)―

Beta1.20

Next Earnings

Mar 23, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.20

Shares Outstanding99,146,740

10 Day Avg. Volume745,110

30 Day Avg. Volume882,734

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.91

Price to Sales (P/S)4.82

P/FCF Ratio-1.91

Enterprise Value/Market Cap1.38

Enterprise Value/Revenue28.95

Enterprise Value/Gross Profit35.64

Enterprise Value/Ebitda-5.75

Forecast

1Y Price Target

$11.00

Price Target Upside163.79% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.65

Revenue Forecast (FY)$15.98M

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Gross MarginsRapid top-line growth combined with strong gross margins indicates improving commercial traction and attractive economics on revenue generated. If this growth continues, it could provide operating leverage over time and help narrow the substantial gap between current sales and the company’s cost base.

Low Financial LeverageVery low debt relative to equity gives X4 greater balance-sheet flexibility while it funds clinical development and prepares for potential commercialization. Its sizable asset and equity base can help support strategic execution, although sustained losses still mean that financial strength must be preserved.

Mavorixafor Development And Market PositionA focused rare-hematology strategy built around a lead asset with late-stage development and long expected patent protection could create a durable commercial opportunity if clinical and regulatory objectives are achieved. Concentrating resources on mavorixafor may also improve execution around its key growth driver.

Bears Say

Persistent Operating LossesThe scale of current losses shows that revenue remains far below the level needed to support the business structure. Deeply negative operating margins could persist through additional development and launch spending, delaying breakeven and making future earnings dependent on substantial revenue growth or cost reductions.

Heavy Cash BurnX4 continues to consume significant cash to fund operations, and the improvement in free cash flow has not changed its negative absolute level. Continued development spending before revenue scales could require additional external funding, limiting financial flexibility and increasing dilution or financing risk.

Secured Financing ObligationsThe $150 million facility extends funding capacity but adds secured obligations, variable financing costs and operating covenants. These terms can constrain capital allocation and increase repayment pressure if clinical progress, future revenue or market capitalization do not develop as planned before maturity.

X4 Pharmaceuticals News

X4 Pharmaceuticals Highlights Strategic Focus on Rare Hematology

X4 Pharmaceuticals ( ($XFOR) ) has issued an announcement. On October 29, 2026, X4 Pharmaceuticals announced that it...

3d ago

XFOR

X4 Pharmaceuticals Secures New $150 Million Term Loan

X4 Pharmaceuticals ( ($XFOR) ) has provided an update. On October 7, 2026, X4 Pharmaceuticals entered a senior...

23d ago

XFOR

X4 Pharmaceuticals Advances Mavorixafor Strategy in Chronic Neutropenia

X4 Pharmaceuticals ( ($XFOR) ) has issued an announcement. On September 8, 2026, X4 Pharmaceuticals posted an updated...

2M ago

XFOR

X4 Pharmaceuticals gains FDA support for 4WARD trial

X4 Pharmaceuticals ( ($XFOR) ) has issued an update. X4 Pharmaceuticals, a Boston-based biopharmaceutical company specializing in therapies...

2M ago

XFOR

X4 Pharmaceuticals announces results from Type C Meeting with FDA

X4 Pharmaceuticals (XFOR) announced the outcome of its Type C Meeting with the FDA related to the global...

2M ago

XFOR

X4 Pharmaceuticals treatment of congenital neutropenia gets orphan designation

X4 Pharmaceuticals (XFOR)’ mavorixafor was granted FDA orphan designation as a treatment of congenital neutropenia, according to a...

2M ago

XFOR

X4 Pharmaceuticals reports Q2 EPS (13c), consensus (18c)

Reports Q2 revenue $8.81M, consensus $2.42M. “Since we began leading X4 last August, we have taken meaningful actions...

3M ago

XFOR

X4’s Mavorixafor Liver Study Completion: What Investors Should Watch Next

X4 Pharmaceuticals ($XFOR) announced an update on their ongoing clinical study. The study An Open-label, Non-randomized Study to...

4M ago

XFOR

X4 Pharmaceuticals initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of X4 Pharmaceuticals (XFOR) with an Overweight rating and $11 price target The firm...

4M ago

XFOR

X4 Pharmaceuticals Expands Board with New Independent Director

The latest update is out from X4 Pharmaceuticals ( ($XFOR) ). On June 30, 2026, X4 Pharmaceuticals appointed...

4M ago

XFOR

X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board

X4 Pharmaceuticals (XFOR) announced the appointment of Kelly Gold to the company’s board of directors effective July 1,...

4M ago

CAMP

XFOR

X4, TripAdvisor, Heron, DigitalOcean, Shake Shack Trending

Analysts are intrested in these 5 stocks: ( ($XFOR) ), ( ($TRIP) ), ( ($HRTX) ), ( ($DOCN)...

5M ago

DOCN

HRTX

X4 Pharmaceuticals initiated with an Outperform at Leerink

Leerink analyst Thomas Smith initiated coverage of X4 Pharmaceuticals (XFOR) with an Outperform rating and $12 price target...

5M ago

XFOR

Six new option listings on May 13th

New option listings for May 13th include Franklin FTSE South Korea ETF (FLKR), Blackhawk Network Holdings Inc (HAWK),...

6M ago

POW

HAWK

XFOR FAQ

What was X4 Pharmaceuticals Inc’s price range in the past 12 months?

X4 Pharmaceuticals Inc lowest stock price was $2.43 and its highest was $4.83 in the past 12 months.

What is X4 Pharmaceuticals Inc’s market cap?

X4 Pharmaceuticals Inc’s market cap is $332.14M.

When is X4 Pharmaceuticals Inc’s upcoming earnings report date?

X4 Pharmaceuticals Inc’s upcoming earnings report date is Mar 23, 2027 which is in 142 days.

How were X4 Pharmaceuticals Inc’s earnings last quarter?

X4 Pharmaceuticals Inc released its earnings results on Aug 06, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.176 by $0.046.

Is X4 Pharmaceuticals Inc overvalued?

According to Wall Street analysts X4 Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does X4 Pharmaceuticals Inc pay dividends?

X4 Pharmaceuticals Inc does not currently pay dividends.

What is X4 Pharmaceuticals Inc’s EPS estimate?

X4 Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does X4 Pharmaceuticals Inc have?

X4 Pharmaceuticals Inc has 99,146,740 shares outstanding.

What happened to X4 Pharmaceuticals Inc’s price movement after its last earnings report?

X4 Pharmaceuticals Inc reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.176. Following the earnings report the stock price went up 0.299%.

Which hedge fund is a major shareholder of X4 Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in XFOR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

X4 Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-63.05%

Trailing 12-Months

Asset Growth

140.63%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.

X4 Pharmaceuticals (XFOR) Earnings & Revenues

Historic Earnings Reports

XFOR Stock 12 Month Forecast

Average Price Target

$11.00

▲(163.79% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","7":"$7","10":"$10","13":"$13"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4,7,10,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.83,3.5353846153846153,4.240769230769231,4.946153846153846,5.651538461538461,6.356923076923077,7.062307692307693,7.7676923076923075,8.473076923076924,9.178461538461539,9.883846153846154,10.58923076923077,11.294615384615385,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.83,3.4584615384615383,4.086923076923076,4.7153846153846155,5.343846153846154,5.972307692307692,6.600769230769231,7.229230769230769,7.857692307692307,8.486153846153845,9.114615384615384,9.743076923076924,10.37153846153846,{"y":11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.83,3.3815384615384616,3.933076923076923,4.484615384615385,5.036153846153846,5.587692307692308,6.139230769230769,6.690769230769231,7.242307692307692,7.793846153846154,8.345384615384615,8.896923076923077,9.448461538461538,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.15,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.35,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.11,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.085,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.07,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >